§ BIOTECHNOLOGY
USD · BiotechnologyORKA
ORUKA THERAPEUTICS INC
USDSector · Biotechnology
§ 01 · PRICE
Price action
1D5D1M6MYTD1YMAX
§ 03 · SIGNAL STACK · WHAT THE INPUTS SAY
13F FLOW
200 increased/new, 51 decreased/exited (13F)
AC 13F Analysis
§ 05 · WHO OWNS IT
Top institutional holders
| Fund | Shares | % port | Δ Q/Q |
|---|---|---|---|
| Fidelity Management | 7.4M | 0.0% | +2% |
| Venrock Adviser, LLC | 4.1M | 7.6% | ±0% |
| Fairmount Funds Management LLC | 3.7M | 13.1% | ±0% |
| BlackRock, Inc. | 3.5M | 0.0% | −0% |
| Viking Global | 2.7M | 0.4% | ±0% |
| Paradigm Biocapital Advisors LP | 2.3M | 2.3% | +36% |
◇ AC INTELLIGENCE
Top institutional owners for ORKA as of the most recent 13F reporting period (Q1 2026 · Period ended Mar 31). Δ Q/Q reflects share-count change vs. the prior filing — positive green means adding, negative red means trimming. Cross-reference with the ownership-mix bars below to see which strategy cohort is driving the flow.
§ 06 · WHO OWNS IT · BY STRATEGY
OTHER75.8% · 128 holders
QUALITY / COMPOUNDER18.6% · 15 holders
PASSIVE / INDEX10.1% · 8 holders
TACTICAL / MACRO7.4% · 2 holders
DEALER / BANK6.2% · 18 holders
INCOME / DEFENSIVE0.5% · 10 holders
GROWTH / MOMENTUM0.1% · 1 holder
SYSTEMATIC / QUANT0.1% · 3 holders
◇ AC INTELLIGENCE
Ownership mix by behavioral cohort. Top bars indicate which style of capital dominates the float — passive indexing, quality compounders, dealer/bank, systematic quant, etc. Big quality-compounder share means concentrated active conviction; heavy passive share means flows are dictated by index rebalances, not fundamentals.
§ 07 · INSIDER ACTIVITY · LAST 180 DAYS
NO INSIDER FILINGS
◇ AC INTELLIGENCE
No Form 4 filings on record for ORKA in the last 180 days.